“More than half of patients (60%) diagnosed with advanced forms of lung cancer who took lorlatinib were still alive five years later with no progression in their disease, data presented at the world’s largest cancer conference showed. The rate was 8% in patients treated with a standard drug, the trial found.

The results are the longest progression-free survival (PFS) outcomes ever recorded in patients with non-small cell lung cancer, the world’s most common form of the disease.”

From The Guardian.